A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness

Inclusion Criteria:

   - For low-risk participant arms 9-11 only: Are greater than or equal to (≥)18 and less
   than (<)65 years of age at the time of randomization and do not have the risk factors
   defined in the bullet point directly below

   - For high-risk participant arms 12 and 13 only:

   -- Are ≥18 years of age and satisfy at least one of the following risk factors at the
   time of screening

      - Are ≥65 years of age

      - Have a body mass index (BMI) ≥ 35

      - Have chronic kidney disease

      - Have type 1 or type 2 diabetes

      - Have immunosuppressive disease

      - Are currently receiving immunosuppressive treatment, or

      - Are ≥55 years of age AND have

         - cardiovascular disease, OR

         - hypertension, OR

         - chronic obstructive pulmonary disease or other chronic respiratory disease

   - For high-risk participant arms 12 and 13 only:

      - Are 12-17 years of age (inclusive) AND satisfy at least one of the following risk
      factors at the time of screening

         - Have a BMI ≥85th percentile for their age and gender based on CDC growth
         charts, https://www.cdc.gov/growthcharts/clinical_charts.htm

         - Have sickle cell disease

         - Have congenital or acquired heart disease

         - Have neurodevelopmental disorders, for example, cerebral palsy

         - Have a medical-related technological dependence, for example, tracheostomy,
         gastrostomy, or positive pressure ventilation (not related to COVID-19)

         - Have asthma or reactive airway or other chronic respiratory disease that
         requires daily medication for control

         - Have type 1 or type 2 diabetes

         - Have chronic kidney disease

         - Have immunosuppressive disease, or

         - Are currently receiving immunosuppressive treatment.

For high-risk participants arm 14 only:

   - Are ≥12 years of age and satisfy at least one of the following risk factors at the
   time of screening Are ≥65 years of age

   - Are adults (≥18 years of age) with BMI >25 kg/m2 , or if age 12-17, have BMI ≥85th
   percentile for their age and gender based on CDC growth charts

   - Have chronic kidney disease

   - Have type 1 or type 2 diabetes

   - Have immunosuppressive disease

   - Are currently receiving immunosuppressive treatment

   - Have cardiovascular disease (including congenital heart disease) or hypertension

   - Have chronic lung diseases (for example, chronic obstructive pulmonary disease, asthma
   [moderate-to-severe], interstitial lung disease, cystic fibrosis and pulmonary
   hypertension)

   - Have sickle cell disease

   - Have neurodevelopmental disorder (for example, cerebral palsy) or other conditions
   that confer medical complexity (for example, genetic or metabolic syndromes and severe
   congenital anomalies)

   - Have a medical-related technological dependence (for example, tracheostomy,
   gastrostomy, or positive pressure ventilation [not related to COVID-19]

   - Are currently not hospitalized

   - Have one or more mild or moderate COVID-19 symptoms: Fever, cough, sore throat,
   malaise, headache, muscle pain, gastrointestinal symptoms, or shortness of breath with
   exertion, nasal congestion or runny nose, new loss of smell, chills

   - Must have sample taken for test confirming viral infection no more than 3 days prior
   to starting the drug infusion

   - Are men or non-pregnant women who agree to contraceptive requirements

   - Understand and agree to comply with planned study procedures

   - Agree to the collection of nasopharyngeal swabs and venous blood

   - The participant or legally authorized representative give signed informed consent
   and/or assent

Exclusion Criteria:

   - For low-risk participants only: BMI ≥35

   - Have oxygen saturation (SpO2) less than or equal to (≤)93 percent (%) on room air at
   sea level or ratio of arterial oxygen partial pressure (PaO2 in millimeters of
   mercury) to fractional inspired oxygen (FiO2) <300, respiratory rate ≥30 per minute,
   heart rate ≥125 per minute

   - Require mechanical ventilation or anticipated impending need for mechanical
   ventilation

   - Have known allergies to any of the components used in the formulation of the
   interventions

   - Have hemodynamic instability requiring use of pressors within 24 hours of
   randomization

   - Suspected or proven serious, active bacterial, fungal, viral, or other infection
   (besides COVID-19) that in the opinion of the investigator could constitute a risk
   when taking intervention

   - Have any co-morbidity requiring surgery within <7 days, or that is considered
   life-threatening within 29 days

   - Have any serious concomitant systemic disease, condition or disorder that, in the
   opinion of the investigator, should preclude participation in this study

   - Have a history of a positive severe acute respiratory syndrome coronavirus 2
   (SARS-CoV-2) test prior to the one serving as eligibility for this study

   - Have received an investigational intervention for SARS-CoV-2 prophylaxis within 30
   days before dosing

   - Have received treatment with a SARS-CoV-2 specific monoclonal antibody

   - Have a history of convalescent COVID-19 plasma treatment

   - For low-risk arms only: have received a SARS-CoV-2 vaccine or have participated in a
   previous SARS-CoV-2 vaccine study and are currently blinded to treatment allotment

   - Have participated, within the last 30 days, in a clinical study involving an
   investigational intervention. If the previous investigational intervention has a long
   half-life, 5 half-lives or 30 days, whichever is longer, should have passed

   - Are concurrently enrolled in any other type of medical research judged not to be
   scientifically or medically compatible with this study

   - Are pregnant or breast feeding

   - Are investigator site personnel directly affiliated with this study

   - Have body weight <40 kilograms